Evidence map›Paper›PMID 40534681›Full record

ArticleACS pharmacology & translational science2025

NARI-29: A Novel Epalrestat Derivative Attenuates Pulmonary Fibrosis by Modulating the TGF-β/Smad Signaling.

Sai Balaji Andugulapati, Vaishnavi Kambhampati, Abhisheik Eedara, Jagadeesh Kumar Gangasani, Harish Kumar B, V G M Naidu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sai Balaji AndugulapatiDepartment of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India.ORCID https://orcid.org/0000-0002-7591-737X
Vaishnavi KambhampatiDepartment of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India.ORCID https://orcid.org/0009-0004-6457-6639
Abhisheik EedaraDepartment of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India.ORCID https://orcid.org/0009-0006-7768-8079
Jagadeesh Kumar GangasaniDepartment of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India.
Harish Kumar BDepartment of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India.
V G M NaiduDepartment of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis is a chronic and debilitating lung disease marked by excessive collagen and extracellular matrix accumulation, leading to lung scarring and impaired lung function. Though pirfenidone and nintedanib are approved drugs, their efficacy is suboptimal. The current study aims to examine the antifibrotic activity of a novel epalrestat (aldose reductase) analog (NARI-29) using

Indexed as

aldose reductasecollagenFlexiVentmyofibroblastsrespiratory resistance

Identifiers

PMID40534681
PMCPMC12171895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.